Intrauterine diseases
Conditions
Interventions
Group T1:Propofol at 2 mg/kg was administered for sedation. In the up-and-down sequential trial, the initial dose of tiglidine for the first patient was 10 µg/kg, with adjacent doses increased or decr
Group T2:Group T received the optimal effective dose determined by the up-and-down sequential trial.
Group S:Group S received 0.3 mcg/kg sufentanil.
Sponsors
Guangzhou Women and Children Medical Center Liuzhou Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Patients aged over 18 years, with American Society of Anesthesiologists (ASA) physical status I to III, scheduled for daytime hysteroscopic surgery.
Exclusion criteria
Exclusion criteria: 1.Patients who do not consent to participate in the clinical study; 2.Allergy to opioids or local anesthetics; 3.Patients with chronic pain requiring chronic preoperative opioid analgesic use; 4.Previous history of dementia, psychosis, or other central nervous system disorders; 5.Poor general condition of the patient, with a history of severe diseases involving the cardiovascular, respiratory, digestive, urinary systems, etc.; 6.Patients who have experienced any of the following conditions within 12 months prior to surgery: myocardial infarction, severe/unstable angina, coronary artery bypass grafting, congestive heart failure, cerebrovascular accident, pulmonary embolism; 7.Patients who are unable to cooperate with follow-up or have poor compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of postoperative nausea and vomiting; | — |
Secondary
| Measure | Time frame |
|---|---|
| Heart Rate;Mean Arterial Pressure;Adverse reaction; | — |
Countries
China
Contacts
Public ContactLingyu Wang
Guangzhou Women and Children Medical Center Liuzhou Hospital
Outcome results
None listed